ストックスクリーナーアプリを入手
146.64
2.88%
-4.355
アフターアワーズ：
146.56
-0.08
-0.05%
前日終値:
$151.00
開ける：
$146.98
24時間の取引高:
6.02M
Relative Volume:
0.85
時価総額：
$181.83B
収益：
$29.79B
当期純損益:
$9.22B
株価収益率:
19.95
EPS:
7.3494
ネットキャッシュフロー:
$10.23B
1週間 パフォーマンス:
-2.19%
1か月 パフォーマンス:
+10.08%
6か月 パフォーマンス:
+1.88%
1年 パフォーマンス:
+26.54%
1日の値動き範囲:
$145.45
$148.65
1週間の範囲:
$145.45
$152.55
52週間の値動き範囲:
$108.46
$157.29
Gilead Sciences Inc Stock (GILD) Company Profile
Compare GILD vs LLY, JNJ, ABBV, MRK, NVS
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
GILD
Gilead Sciences Inc
|
146.64 | 187.23B | 29.79B | 9.22B | 10.23B | 7.3494 |
LLY
Lilly Eli Co
|
1,123.91 | 1.02T | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
269.12 | 663.28B | 97.93B | 21.04B | 17.80B | 8.6278 |
ABBV
Abbvie Inc
|
248.78 | 453.19B | 62.82B | 3.60B | 19.98B | 2.0274 |
MRK
Merck Co Inc
|
148.46 | 370.89B | 65.51B | 8.93B | 14.12B | 3.5532 |
NVS
Novartis Ag Adr
|
137.70 | 304.10B | 54.66B | 13.58B | 16.05B | 7.0171 |
Gilead Sciences Inc Stock (GILD) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-03-10 | 開始されました | Jefferies | Buy |
| 2026-02-20 | 開始されました | Barclays | Equal Weight |
| 2026-02-11 | 繰り返されました | Needham | Buy |
| 2026-01-07 | 再開されました | UBS | Buy |
| 2025-11-24 | 再開されました | Truist | Buy |
| 2025-11-13 | 開始されました | Scotiabank | Sector Outperform |
| 2025-08-19 | アップグレード | Daiwa Securities | Neutral → Outperform |
| 2025-08-08 | アップグレード | Truist | Hold → Buy |
| 2025-07-25 | アップグレード | Needham | Hold → Buy |
| 2025-04-22 | 再開されました | Cantor Fitzgerald | Overweight |
| 2025-03-04 | 繰り返されました | Oppenheimer | Outperform |
| 2025-02-18 | アップグレード | Deutsche Bank | Hold → Buy |
| 2025-02-13 | アップグレード | DZ Bank | Hold → Buy |
| 2025-01-10 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2024-12-10 | 再開されました | BofA Securities | Buy |
| 2024-11-15 | 開始されました | Wolfe Research | Outperform |
| 2024-11-14 | 開始されました | Citigroup | Buy |
| 2024-11-08 | ダウングレード | Maxim Group | Buy → Hold |
| 2024-10-21 | アップグレード | Leerink Partners | Market Perform → Outperform |
| 2024-10-17 | 開始されました | Bernstein | Outperform |
| 2024-10-07 | アップグレード | Wells Fargo | Equal Weight → Overweight |
| 2024-07-08 | アップグレード | Raymond James | Mkt Perform → Outperform |
| 2024-05-01 | 繰り返されました | Maxim Group | Buy |
| 2024-04-24 | アップグレード | HSBC Securities | Reduce → Hold |
| 2024-02-22 | ダウングレード | Truist | Buy → Hold |
| 2023-11-09 | 開始されました | Deutsche Bank | Hold |
| 2023-09-08 | アップグレード | BofA Securities | Neutral → Buy |
| 2023-09-06 | 開始されました | HSBC Securities | Reduce |
| 2023-07-24 | 繰り返されました | Barclays | Equal Weight |
| 2023-05-16 | アップグレード | BMO Capital Markets | Market Perform → Outperform |
| 2023-04-28 | 再開されました | Piper Sandler | Overweight |
| 2023-01-03 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2022-12-13 | 再開されました | BofA Securities | Neutral |
| 2022-12-09 | ダウングレード | DZ Bank | Buy → Hold |
| 2022-10-31 | アップグレード | Barclays | Underweight → Equal Weight |
| 2022-10-28 | 繰り返されました | BMO Capital Markets | Market Perform |
| 2022-10-28 | 繰り返されました | Cowen | Outperform |
| 2022-10-28 | 繰り返されました | JP Morgan | Overweight |
| 2022-10-28 | 繰り返されました | Jefferies | Buy |
| 2022-10-28 | アップグレード | Piper Sandler | Neutral → Overweight |
| 2022-10-28 | 繰り返されました | RBC Capital Mkts | Outperform |
| 2022-10-28 | アップグレード | Truist | Hold → Buy |
| 2022-10-28 | 繰り返されました | Wells Fargo | Equal Weight |
| 2022-10-04 | アップグレード | JP Morgan | Neutral → Overweight |
| 2022-07-13 | 開始されました | Cantor Fitzgerald | Neutral |
| 2022-05-23 | 開始されました | SVB Leerink | Mkt Perform |
| 2022-02-28 | ダウングレード | BMO Capital Markets | Outperform → Market Perform |
| 2022-02-02 | 繰り返されました | BMO Capital Markets | Outperform |
| 2022-02-02 | 繰り返されました | BofA Securities | Neutral |
| 2022-02-02 | 繰り返されました | RBC Capital Mkts | Outperform |
| 2022-02-02 | 繰り返されました | Truist | Hold |
| 2022-02-02 | 繰り返されました | Wells Fargo | Equal Weight |
| 2022-01-28 | アップグレード | Argus | Hold → Buy |
| 2022-01-06 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2021-12-09 | 再開されました | Wells Fargo | Equal Weight |
| 2021-12-06 | 開始されました | Goldman | Neutral |
| 2021-11-19 | アップグレード | BMO Capital Markets | Market Perform → Outperform |
| 2021-11-19 | 再開されました | Piper Sandler | Neutral |
| 2021-10-20 | 再開されました | Cowen | Outperform |
| 2021-07-30 | 繰り返されました | BMO Capital Markets | Market Perform |
| 2021-07-30 | 繰り返されました | RBC Capital Mkts | Outperform |
| 2021-04-01 | アップグレード | Bernstein | Mkt Perform → Outperform |
| 2021-03-30 | アップグレード | Redburn | Neutral → Buy |
| 2021-01-19 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2021-01-04 | アップグレード | Guggenheim | Neutral → Buy |
| 2020-11-03 | 再開されました | Morgan Stanley | Equal-Weight |
| 2020-10-28 | 開始されました | UBS | Neutral |
| 2020-09-30 | 再開されました | Jefferies | Buy |
| 2020-09-15 | アップグレード | Maxim Group | Hold → Buy |
| 2020-07-31 | 繰り返されました | Credit Suisse | Neutral |
| 2020-07-31 | 繰り返されました | Morgan Stanley | Equal-Weight |
| 2020-07-31 | 繰り返されました | Piper Sandler | Overweight |
| 2020-07-31 | 繰り返されました | RBC Capital Mkts | Outperform |
| 2020-07-31 | 繰り返されました | SunTrust | Hold |
| 2020-07-31 | 繰り返されました | Wells Fargo | Equal Weight |
| 2020-07-20 | アップグレード | Credit Suisse | Underperform → Neutral |
| 2020-06-03 | アップグレード | SVB Leerink | Mkt Perform → Outperform |
| 2020-05-26 | アップグレード | SunTrust | Sell → Hold |
| 2020-05-01 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2020-05-01 | ダウングレード | Raymond James | Outperform → Mkt Perform |
| 2020-05-01 | ダウングレード | SunTrust | Hold → Sell |
| 2020-04-27 | ダウングレード | UBS | Buy → Neutral |
| 2020-04-20 | ダウングレード | BMO Capital Markets | Outperform → Market Perform |
| 2020-04-20 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2020-04-17 | ダウングレード | CFRA | Hold → Sell |
すべてを表示
Gilead Sciences Inc (GILD) 最新ニュース
How Bixlenvo Approval At Gilead Sciences (GILD) Has Changed Its Investment Story - simplywall.st
Gilead opens new building on existing Foster City campus - NBC Bay Area
Gilead National Ribbon Cutting Ceremony - Post Register
Gilead Sciences (GILD) Suffers a Larger Drop Than the General Market: Key Insights - Yahoo Finance
Assembly Bio stock gains after exercising Gilead profit option By Investing.com - Investing.com Nigeria
Assembly Bio stock gains after exercising Gilead profit option - Investing.com India
Assembly Biosciences Exercises U.S. Profit-Share Option with Gilead for HSV Helicase-Primase Inhibitor Program - The Manila Times
A $75 million Gilead payment is due in Q4, while Assembly Bio expects cash to fund operations into 2029. - Stock Titan
Gilead Opens 182,000-Square-Foot Research Center in Foster City - Contract Pharma
Gilead Sciences Inc Stock (GILD) Moved Down by 3.26% on Sep 8: Drivers Behind the Movement - TradingKey
Gilead Opens State-of-the-Art Research Center to Advance the Next Generation of Medicines - Gilead Sciences
Gilead Sciences stock gains on fresh analyst buy rating and Q2 loss swing - AD HOC NEWS
Gilead Sciences Slides 3.4% as Investors Digest Prior Gains and Ongoing Pricing Risks - Quiver Quantitative
Gilead opens research center as $32 billion US build-out continues - The Pharma Letter
Gilead Sciences, Inc. $GILD Shares Purchased by Groupe la Francaise - MarketBeat
California State Teachers Retirement System Has $30.47 Billion Stake in Gilead Sciences, Inc. $GILD - MarketBeat
Bixlenvo Gives Gilead a New HIV Growth Path. How Large is the Market? - Yahoo Finance
[Press release] FDA approves Gilead’s Bixlenvo™, a new once-daily single tablet option for virologically suppressed adults with HIV, including those on complex regimens - European AIDS Treatment Group
Gilead Sciences stock gains after narrowing Q2 loss and firming 2026 guidance - AD HOC NEWS
Unlocking Opportunity: Dominate the Market of CAR/TCR/TIL Therapies in Oncology with Confidence. See Exactly How Gilead, Cellectis, MediGene, GenScript, and CARsgen Are Positioned to Win Through 870+ Rivals - GlobeNewswire Inc.
Gilead Sciences, Inc. $GILD Holdings Raised by HighTower Advisors LLC - MarketBeat
VIRGINIA RETIREMENT SYSTEMS ET Al Takes $130.42 Million Position in Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Sciences, Inc. (GILD) Stock Analysis: Evaluating the Prospects with a 4.25% Potential Upside - DirectorsTalk Interviews
Could Gilead Sciences (NASDAQ:GILD) Remain a Nasdaq Focus? - Kalkine Media
Amundi Has $1.23 Billion Holdings in Gilead Sciences, Inc. $GILD - MarketBeat
Saudi Central Bank Acquires 41,091 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Sciences Strategically Prepares for HIV Market Changes - Intellectia AI
Gilead Sciences Just Won Its Third FDA Approval in Less Than 4 Months. Is the Stock Still Underrating This Turnaround Play? - Yahoo Finance
Gilead Sciences (NASDAQ:GILD) Lowered to Hold Rating by Wall Street Zen - MarketBeat
Will New HIV and Oncology Approvals Redefine Gilead Sciences' (GILD) Treatment Platform Narrative? - Yahoo Finance
Gilead Keeps Writing Bigger Checks—But Can the Drugs Keep Paying for Them? - AOL.com
Q&A: Gilead's Betty Chiang on what Bixlenvo means for HIV patients on complex regimens - The Pharma Letter
Gilead Sciences (NASDAQ:GILD): A Quality Dividend Stock for Income Investors - ChartMill
NEOS Investment Management LLC Has $120.08 Million Position in Gilead Sciences, Inc. $GILD - MarketBeat
TD Waterhouse Canada Inc. Sells 70,572 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
AXQ Capital LP Makes New Investment in Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Sciences Inc. stock underperforms Thursday when compared to competitors despite daily gains - MarketWatch
Gilead Sciences (GILD) Chairman & CEO Daniel O'Day Sells 15,000 Shares - gurufocus.com
Why Is Gilead (GILD) Up 13.6% Since Last Earnings Report? - Yahoo Finance
Gilead Sciences Q1 EPS Estimate Raised by Zacks Research - MarketBeat
Is Gilead Sciences Stock Outperforming the S&P 500? - Yahoo Finance
Nykredit A S Makes New $177.13 Million Investment in Gilead Sciences, Inc. $GILD - MarketBeat
iSAM Funds UK Ltd Buys New Stake in Gilead Sciences, Inc. $GILD - MarketBeat
B. Metzler seel. Sohn & Co. AG Boosts Stock Position in Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Sciences (NASDAQ:GILD) CEO Sells 15,000 Shares of Stock - MarketBeat
Gilead (NASDAQ: GILD) CEO sells 15,000 shares near $150 - Stock Titan
Gilead Sciences stock gains as analysts turn more positive - AD HOC NEWS
Gilead Sciences (NASDAQ:GILD) Raised to "Strong-Buy" at Zacks Research - MarketBeat
Zacks Research Lifts Earnings Estimates for Gilead Sciences - MarketBeat
Gilead Sciences Inc. stock outperforms competitors on strong trading day - MarketWatch
Can Bixlenvo Unlock New Growth for Gilead's HIV Business? - Yahoo Finance
Gilead Sciences Inc (GILD) 財務データ
収益
当期純利益
現金流量
EPS
3.09%
大文字化:
|
ボリューム (24 時間):